HAOXI HEALTH TECHNOLOGY and Eaglepoint AI Forge Strategic Partnership to Enter AI-Powered Health Management Track

Rhea-AI Summary

Haoxi Health (NASDAQ: HAO) and Eaglepoint AI (subsidiary of GMM) signed a three-year strategic cooperation to develop an AI health management platform in China. The partnership will combine Haoxi's marketing networks and user reach with Eaglepoint's Aquila data engine for R&D, model training, and a SaaS release called "AI Digital Health Manager" targeting sub-healthy and chronic disease populations.

The collaboration covers intelligent nutrition, chronic disease risk assessment, and digital therapeutics, with Eaglepoint handling model iteration and data-security compliance.

Positive

• Three-year strategic agreement to develop AI health management platform
• Launch of AI Digital Health Manager SaaS targeting sub-healthy and chronic disease users
• Eaglepoint's Aquila platform drove 3.5x faster model iteration efficiency (as stated)
• Haoxi's marketing reach backed by "tens of billions" of online advertising data points

Negative

• No financial terms or revenue projections disclosed for the three-year cooperation
• No concrete commercial timelines beyond an initial "first phase" launch

Key Figures

Strategic cooperation term: 3 years Model iteration gain: 3.5 times ATM program size: $80,000,000 +5 more

8 metrics

Strategic cooperation term 3 years Length of Haoxi–Eaglepoint AI strategic agreement

Model iteration gain 3.5 times Efficiency improvement from Eaglepoint’s Aquila platform vs mainstream models

ATM program size $80,000,000 Class A share at-the-market program established January 23, 2026

ATM commission 2.5% Sales agent commission on ATM gross proceeds

Reference price $1.56 Class A reference price used in January 23, 2026 prospectus

FY2025 revenue $32.80 million Revenue year ended June 30, 2025

FY2025 net income $3,876,680 Net income year ended June 30, 2025

IPO gross proceeds $11,040,000 IPO proceeds at $4.00 per share, including over-allotment

Market Reality Check

Price: $1.11 Vol: Volume 912 is only 0.07x ...

low vol

$1.11 Last Close

Volume Volume 912 is only 0.07x the 20-day average of 13,936, indicating limited participation. low

Technical Trading above the 200-day MA of 1.23 with price at 1.285 pre-announcement.

Peers on Argus

HAO was up 5.76% while key peers were mixed: CNET -3.55%, DRCT -1.92%, CHR +2.42...

HAO was up 5.76% while key peers were mixed: CNET -3.55%, DRCT -1.92%, CHR +2.42%, and STFS +27.5%, suggesting a stock-specific move tied to the AI partnership news.

Previous Partnership,AI Reports

1 past event · Latest: Sep 25 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 25	AI partnership	Positive	+11.3%	Announced AI marketing partnership integrating Gausspeed with Haoxi’s applications.

Pattern Detected

Prior AI partnership news in 2024 also saw a positive price reaction, suggesting investors have historically rewarded AI-related collaborations.

Recent Company History

In September 2024, Haoxi Health announced a strategic AI marketing partnership with a Global Mofy AI subsidiary, integrating the Gausspeed generative AI platform to enhance data analysis, creative automation, and decision-making. The stock moved +11.27% over 24 hours. The current agreement with another Global Mofy AI subsidiary, Eaglepoint AI, again focuses on AI-driven capabilities, this time for health management in China, extending the company’s AI collaboration theme from marketing into healthcare applications.

Historical Comparison

+11.3% avg move · Over the past 6 months, Haoxi had 1 prior AI partnership headline with an average +11.27% move, so s...

partnership,AI

+11.3%

Average Historical Move partnership,AI

Over the past 6 months, Haoxi had 1 prior AI partnership headline with an average +11.27% move, so similar collaborations have previously drawn a constructive market response.

AI collaborations evolved from marketing-focused solutions in 2024 to a broader AI-powered health management platform in 2026, extending use cases into preventive healthcare.

Market Pulse Summary

This announcement details a three-year collaboration between Haoxi Health and Eaglepoint AI to build...

Analysis

This announcement details a three-year collaboration between Haoxi Health and Eaglepoint AI to build an AI health management platform in China, including an “AI Digital Health Manager” SaaS offering and digital therapeutics-oriented capabilities. It follows a prior AI marketing partnership in 2024 with another Global Mofy AI subsidiary, indicating a consistent AI strategy. Investors may track execution milestones, adoption by healthcare clients, and how these initiatives intersect with financing and dilution dynamics disclosed in recent filings.

Key Terms

digital therapeutics, model training

2 terms

digital therapeutics medical

"preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics."

Digital therapeutics are clinically proven software programs or apps designed to prevent, manage or treat medical conditions, often used alongside or instead of drugs and devices. They matter to investors because they can scale like software, require regulatory approval and payment from insurers or health systems, and thus offer potential recurring revenue, lower delivery costs and new market opportunities in healthcare — like a virtual prescription that replaces or enhances traditional treatment.

model training technical

"Eaglepoint AI will be responsible for technical support in model training, data security"

The process of teaching a computer system to recognize patterns and make predictions by feeding it lots of example data and adjusting its internal settings until its answers improve. Investors care because how well a model is trained affects a product’s accuracy, reliability, speed to market, and operating costs, and it can influence competitive advantage, regulatory risk, and potential for biased or unsafe outcomes—like training an employee to perform a critical job correctly.

AI-generated analysis. Not financial advice.

BEIJING, March 03, 2026 (GLOBE NEWSWIRE) -- HAOXI HEALTH TECHNOLOGY LIMITED (NASDAQ: HAO) (the “Haoxi Health”), a U.S. publicly listed company, and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ: GMM), today jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.

Under the agreement, both parties will explore collaboration in the AI-enabled preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics. HAOXI HEALTH plans to contribute its marketing networks to provide user reach and commercial conversion support, while Eaglepoint AI will be responsible for technical support in model training, data security compliance, and algorithm iteration. The first phase of the project will launch the "AI Digital Health Manager" SaaS system targeting sub-healthy and chronic disease populations.

Mr. Fan Zhen, CEO of Haoxi Health, stated: "The company has long served domestic and international healthcare clients, managing tens of billions of online advertising data points. We understand clients' urgent demand for personalized, quantifiable health management solutions. Eaglepoint AI possesses capabilities in data governance and multimodal model evaluation. Its proprietary Aquila platform has achieved automated comparative experiments with mainstream large models including Claude, GPT, and Gemini, improving model iteration efficiency by 3.5 times. We believe this collaboration will integrate HAOXI's marketing traffic advantages with Eaglepoint's algorithmic strengths."

Both parties believe that the collaboration between HAOXI HEALTH and Eaglepoint AI will not only enhance digital marketing ROI for domestic healthcare enterprises but also provide health data pipelines for AI models, contributing to the competitive and cooperative landscape across the "Data + Algorithm + Traffic" dimensions.

About Haoxi Health Technology Limited

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations

ir@haoximedia.com

FAQ

What did Haoxi Health (HAO) announce on March 3, 2026 about AI healthcare?

They announced a three-year strategic cooperation with Eaglepoint AI to build an AI health management platform in China. According to the company, the deal pairs Haoxi's marketing reach with Eaglepoint's Aquila engine for R&D and SaaS deployment.

What is the "AI Digital Health Manager" SaaS that HAO plans to launch?

It is a SaaS system targeting sub-healthy and chronic disease populations for preventive care and management. According to the company, the first phase will focus on intelligent nutrition, risk assessment, and digital therapeutics.

How will Eaglepoint AI contribute technically to the HAO partnership?

Eaglepoint will provide model training, algorithm iteration, and data-security compliance support. According to the company, its Aquila engine has automated comparative experiments and improved model iteration efficiency by 3.5 times.

What role will Haoxi Health (HAO) play in the partnership with Eaglepoint AI?

Haoxi will supply marketing networks, user reach, and commercial conversion support to scale uptake. According to the company, it leverages "tens of billions" of online advertising data points to drive user acquisition.

Does the March 3, 2026 announcement disclose financial terms or revenue impact for HAO?

No, the announcement does not disclose any financial terms, pricing, or projected revenue impact for the cooperation. According to the company, operational and technical responsibilities are described but monetary details were not provided.

What healthcare applications will the HAO and Eaglepoint collaboration explore?

They will explore AI-enabled preventive healthcare: intelligent nutrition, chronic disease risk assessment, and digital therapeutics. According to the company, these areas are the primary focus for the joint platform and initial SaaS offering.